Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2457-2464

  Ormandy, Lars ^a   Hillemann, Tina ^a   Wedemeyer, Heiner ^a   Manns, Michael P ^a   Greten, Tim F ^a   Korangy, Firouzeh ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CYTOKINE; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; ASCITES; BLOOD; CELL POPULATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; FLUORESCENCE ACTIVATED CELL SORTING; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DNA-BINDING PROTEINS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RNA, MESSENGER;

EID: 16844378685     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3232     Document Type: Article

References (46)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
2. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003;21:4329-35.
3. Allgaier HP, Deibert P, Olschewski M, et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection-a single-center analysis including 132 patients. Int J Cancer 1998;79:601-5.
4. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol 1999;17:1047-60.
5. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998;27:407-14.
6. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
7. Onji M, Akbar F, Horiike N. Dendritic cell-based immunotherapy for hepatocellular carcinoma. J Gastroenterol 2001;36:794-7.
8. Ladhams A, Schmidt C, Sing G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002;17:889-96.
9. Korangy F, Ormandy LA, Bleck JS, et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 2004;10:4332-41.
10. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-8.
11. Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002;2:827-34.
12. + suppressor T cells. Immunol Rev 2001;182:58-67.
13. + immunoregulatory cells. J Immunol 2001;167:1137-40.
14. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6.
15. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 1999;59:3128-33.
16. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1.
17. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200:771-82.
18. Mukherji B, Guha A, Chakraborty NG, et al. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 1989;169:1961-76.
19. Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B. Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J Immunol 1990;145:2359-64.
20. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
21. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30.
22. 2- microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. J Immunol Methods 2002;271:125-35.
23. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
24. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
25. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor κ B inflammatory bowel disease. Gut 1998;42:477-84.
26. high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53.
27. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135-42.
28. Levings MK, Sangregorio R, Roncarolo MG. Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193:1295-302.
29. Ramsdell F. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 2003;19:165-8.
30. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-12.
31. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285-94.
32. + regulatory thymocytes. Blood 2003;102:4107-14.
33. Annunziato F, Cosmi L, Liotta F, et al. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med 2002;196:379-87.
34. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor β. J Exp Med 2001;194:629-44.
35. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-96.
36. Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-46.
37. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor foxp3. Science 2003;299:1057-61.
38. + regulatory T cells. Nat Immunol 2003;4:330-6.
39. + regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004;103:3428-30.
40. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003;38:1437-48.
41. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 2002;196:255-60.
42. Dieckmann D, Bruett CH, Ploettner- H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med 2002;196:247-53.
43. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8.
44. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
45. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-8.
46. Greten TF, Schneck JP. Development and use of multimeric major histocompatibility complex molecules. Clin Diagn Lab Immunol 2002;9:216-20.